Comparison of Saphenous Vein Graft Harvested From Upper Versus Lower Leg in Coronary Artery Bypass Grafting

NCT ID: NCT01974492

Last Updated: 2016-07-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

26 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-10-31

Study Completion Date

2016-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In coronary artery bypass grafting, saphenous veins are widely used as a composite grafts that are Y-anastomosed to in-situ left internal thoracic artery. Based on our observation that remodeling of saphenous vein graft differs between those harvested from upper leg vein and lower leg, this study aims to compare histologic and immunohistochemical findings between saphenous vein grafts harvested from upper leg and lower leg.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Inclusion criteria:

* Patients aged from 40 to 75 years with triple vessel disease
* Patients who are eligible for the use of left internal thoracic artery as an in situ primary conduit
* Operation plan: saphenous vein graft will be Y-anastomosed to left internal thoracic artery.
* Patients whose saphenous vein grafts can be harvested from both upper legs and lower legs
* Patients who are eligible for off-pump coronary artery bypass grafting
* Patients who agreed with the participation in the research based on thorough explanation.

Patients will be randomly assigned to upper leg vein (ULV) group and lower leg vein (LLV) group immediately after anesthetic induction.

Pieces of residual saphenous vein graft will be sent for histologic and immunohistochemical examination for the evaluation of endothelial cell preservation and the expression of matrix proteins.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Triple Vessel Disease Unstable Angina Stable Angina Myocardial Infarction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Upper leg vein

Upper leg vein harvesting

Group Type ACTIVE_COMPARATOR

Upper leg vein harvesting

Intervention Type PROCEDURE

Patients whose saphenous veins are harvested from upper legs.

Lower leg vein

Lower leg vein harvesting

Group Type ACTIVE_COMPARATOR

Lower leg vein harvesting

Intervention Type PROCEDURE

Patients whose saphenous veins are harvested from lower legs.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Upper leg vein harvesting

Patients whose saphenous veins are harvested from upper legs.

Intervention Type PROCEDURE

Lower leg vein harvesting

Patients whose saphenous veins are harvested from lower legs.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with multivessel disease who were planned to undergo off-pump coronary artery bypass grafting
* Patients whose left internal thoracic arteries can be used, and whose saphenous vein grafts will be Y-anastomosed to left internal thoracic arteries.
* Patients whose saphenous vein grafts can be harvested from both upper and lower legs.

Exclusion Criteria

* Patients with overt heart failure symptoms
* Patients with intractable ventricular arrhythmia
* Patients with history of cancer or malignancy
* Patients with coagulation or other hematologic disorder
* Patients who needs concomitant cardiac procedures
Minimum Eligible Age

40 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Seoul National University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ki-Bong Kim

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ki-Bong Kim, M.D., Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Seoul National University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Seoul National University Hospital

Seoul, , South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SNUHTS_KBKim_Saphenous

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Radial Artery Versus No-touch Saphenous Vein
NCT06014047 NOT_YET_RECRUITING NA